Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BouNDless: ND0612 vs Oral LD/CD in Parkinson's Disease
NCT04006210Phase 3Active, not recruiting
- Sponsor
- NeuroDerm Ltd.
- Start
- Sep 2019
- Primary completion
- Nov 2022
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of ND0612 in Parkinson's disease (PD) (2 arms), sponsored by NeuroDerm Ltd. Primary endpoint: Change in daily ON time without troublesome dyskinesia at 12 weeks. Started Sep 2019; status: active, not recruiting.
02
Drugs
ND0612
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04006210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04006210.